Which Defensive Stock Has Dominated in 2026: Coca-Cola, Johnson & Johnson, or Procter & Gamble?

Among 2026’s classic defensive blue chips, one name has clearly dominated, and the ranking underneath tells a bigger story about what actually worked this year. The three defensives split into a clear top, middle, and lagging tier. Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) stock was $275.23, up 35% year to date through Friday’s close, powered by oncology and immunology wins and rotation into healthcare during the year’s volatile stretches.

Checking in on other defensive names, Coca-Cola (NYSE:KO) stock came in at $88.07, up 28% over the same stretch, riding pricing power and steady global volume rather than any single dated catalyst. Meanwhile, Procter & Gamble (NYSE:PG) stock was $146.44, up just 4%, trailing both peers and the low-volatility factor.

The framing contrast is instructive. The Invesco S&P 500 Low Volatility ETF (NYSEARCA:SPLV) was up 6% year to date through Friday’s close, while the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) was up 13%. Defensives as a category lagged the broad market this year, yet two of these three names beat SPY anyway. The label described risk, not return.

JNJ’s Pipeline Powers the Lead

Johnson & Johnson’s Innovative Medicine portfolio carried the year. Q2 2026 worldwide sales at Johnson & Johnson reached $25.3 billion with operational growth of 5.6%, and management raised full-year adjusted operational EPS guidance to $11.50 to $11.65. Darzalex sales exceeded $4 billion in the quarter and grew 17.6%, and Tremfya reached $2 billion in quarterly sales with growth of 71%. Q1 2026 set the tone with revenue of $24.06 billion, up 9.9% year over year and adjusted EPS of $2.70.

Beyond that portfolio strength, Johnson & Johnson added the Caplyta franchise through its Intra-Cellular Therapies acquisition, and Caplyta grew 70.9% in Q2 with new patient starts up 122% versus prior year. The company remains on track for a mid-2027 separation of DePuy Synthes and lifted its quarterly dividend to $1.34 per share, its 64th consecutive annual increase (we ranked ten of these long-streak payers by valuation in a free Dividend Kings report). CEO Joaquin Duato stated JNJ has “the strongest portfolio and pipeline in our 140-year history.”

KO’s Pricing Power and PG’s Missing Catalyst

Coca-Cola’s climb came from execution rather than any single event. Q2 2026 organic revenue at Coca-Cola grew 6% and unit case volume grew 5%, and management raised full-year comparable EPS growth guidance to 9% to 10% and free cash flow guidance to $12.4 billion. The result was Coca-Cola’s fifth consecutive EPS beat, alongside operating margin expansion to 34.9% from 34.1% a year earlier. Trademark Coca-Cola posted its strongest volume growth in 17 years excluding COVID-19 recovery, aided by FIFA World Cup activation across more than 180 markets. Latin America revenue grew 16% and North America grew 7%, giving the report unusual geographic breadth.

Procter & Gamble stock’s underperformance can’t be tied to one verified catalyst. Fiscal Q4 2026 delivered core EPS at Procter & Gamble of $1.43 against flat organic sales and a revenue miss, and fiscal 2027 guidance flagged roughly $1 billion after-tax in commodity, energy, and transport headwinds. The company’s operating income fell 9.3% and net income fell 14.8% in the quarter. CEO Shailesh Jejurikar called fiscal 2026 “a year of foundation building.” The market simply preferred Johnson & Johnson’s pipeline and Coca-Cola’s global volume over PG’s rebuild year.

2026 Scorecard

What to Watch Next

Johnson & Johnson’s Enterprise Business Review scheduled Dec 8, 2026 could reinforce or complicate the pipeline narrative and provide fresh color on the DePuy Synthes separation. Coca-Cola holders can watch for continued price/mix balance and the pending African bottling divestiture, which management expects to close toward the end of the third quarter or during the fourth quarter, subject to regulatory approvals. Beyond the divestiture, Coca-Cola also faces an outstanding 11th Circuit Court of Appeals decision in its IRS dispute, with timing unknown.

Procter & Gamble’s investor day on November 19, 2026 in Cincinnati gives management a chance to reset expectations after a fiscal year Jejurikar framed as foundation building. First-quarter fiscal 2027 core EPS at PG is guided to be down 5% or more versus the prior year, so the near-term bar sits low and the setup for a second-half recovery matters more than any single quarter. The company plans approximately $10 billion in dividends and $5 billion in buybacks in fiscal 2027, so capital returns aren’t the concern.

For anyone considering owning shares of this defensive group, the fair read is that healthcare and consumer staples both worked in 2026, unevenly, and the defensive label described risk more than return. Investors could size their positions to reflect what actually happened, tilting toward JNJ and KO while keeping their PG exposure smaller until organic sales reaccelerate and the fiscal 2027 cost pressure clears. A balanced staples-plus-healthcare mix looks like the reasonable posture heading into year-end.

Contact [email protected] for any questions or corrections.